Pancreatic tumors with osteoclast-like giant cells are rare, with only 50 cases published to date. We report a case of a 67-year-old male with a new diagnosis of follicular non-Hodgkin's lymphoma with an incidental pancreatic body mass on abdominal imaging. Cytology from the pancreatic mass obtained via endoscopic ultrasound-directed fine-needle aspiration (EUS-FNA) revealed an undifferentiated carcinoma with osteoclast-like giant cells.
Introduction
Undifferentiated carcinoma with osteoclast-like giant cells (UCWOGC) is a rare abdominal tumor that is estimated to account for 1% of pancreatic tumors. 1, 2 Although this cytologic variant has been identified in other tissues such as the skin, thyroid gland, ovary, and breast, 3 it has been most commonly reported in the pancreas and was first described by Rosai in 1968 . 1, 4 The tumor is often found on imaging and typically appears as a large heterogeneous mass with well-demarcated hyper-and hypoechoic areas that represent necrotic areas and cystic structures, respectively. 1, 5 About 50 reports of this tumor have been described, and most have been in Asia. 6 Case Report The gross specimen appeared as an 11 x 5.5 x 4-cm mass with a focally softened solid portion and a portion of multiple smooth-walled cysts containing mucoid material. The patient did well postoperatively without adjuvant chemotherapy.
Discussion
UCWOGC is a classified by the World Health Organization as a rare variant of ductal adenocarcinoma 7 with two distinct cell lines, including a mononuclear cell line population and osteoclastic tumor cells. 1 The tumor is further described by the Stanford Surgical Pathology Criteria as multinucleated giant cells with malignant background cells. 8 Due to the poor differentiation of the underlying tumor cells, it is unclear where these neoplastic cells originate. Many authors favor an epithelial origin while others favor a mesenchymal origin. 2, 9 UGWOGC is thought to have an equal male-female predominance with an average age of incidence around 60 years. 1 The presentation is variable depending on the location of the tumor within the pancreas; pancreatic head masses present with jaundice and weight loss, and pancreatic body the pancreas. In some studies, 10-year survival with UG-WOGC has been reported, which shows that this tumor may have a better prognosis than undifferentiated carcinoma of the pancreas without osteoclast-like giant cells. 11, 12 In general, the average survival has been shown to be about only 20 months. 10 There have been trials investigating the use of chemotherapeutic agents, such as gemcitabine, but no conclusive evidence has been found to indicate their use.
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Informed consent was obtained for this manuscript. and tail tumors present with abdominal pain. 7 Patients typically present with advanced disease. Imaging, including abdominal ultrasound, CT, and MRI are used for diagnosis of these tumors. These masses are typically further evaluated by EUS-FNA of the mass, as in this case, or through mass resection. In patients with UCWOGC, numerous reports have shown that treatment choice is resection if possible, 6 though resection can rarely be performed since the disease typically presents in advanced stage.
The prognosis of UCWOGC is poor, but it is better than that of ductal carcinomas and pleomorphic giant cell tumors of
